A special study confirmed that this cell construct exhibits CAR-mediated, CD19-dependent activity against autologous B-cells and comparably low inflammatory cytokine production when derived from cells from SLE, SSc, and idiopathic inflammatory myositis (IIM) patients [98]. This evidence concerns the gene CD19 and acquired idiopathic inflammatory myopathy.